NEWPORT BEACH, Calif. , April 16, 2020 (GLOBE NEWSWIRE) -- Evolus , Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced a pre-emptive plan to support the U.S. aesthetic neurotoxin market in light of the

Company Remains Confident in its Intellectual Property and the Overall Merits of the Case NEWPORT BEACH, Calif. , March 04, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS) today provided the following statement: “In several media reports this week, Medytox has made comments on the

NEWPORT BEACH, Calif. , March 03, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that management will be participating in the Barclays 2020 Global Healthcare Conference

Q4 2019 Net Revenue $19.5 Million , Up from $13.2 Million in Q3 2019 Jeuveau ® Achieved Number Three Unit Share Position in the U.S. in 2019 1 Launched Evolux™; Only Practice Loyalty Program to Offer Co-Branded Digital Advertising for Neurotoxins NEWPORT BEACH, Calif. , Feb.

NEWPORT BEACH, Calif. , Feb. 13, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in the 9 th Annual SVB Leerink Global

NEWPORT BEACH, Calif. , Feb. 12, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its fourth quarter and full year 2019 financial results and provide a

Primary Endpoint of Non-Inferiority Achieved with Responder Rates* of 65.02% for PrabotulinumtoxinA and 62.56% for OnabotulinumtoxinA at Week 4 NEWPORT BEACH, Calif. , Jan. 27, 2020 (GLOBE NEWSWIRE) -- Evolus , Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach

Q4 2019 net revenue estimated between $18.5 and $19.5 million ; increased from $13.2 million in Q3 2019 Completed Q4 2019 with over 3,500 purchasing accounts; increased from over 2,000 at end of Q3 2019 Year-end 2019 cash, cash equivalents and short-term investments balance of $129.8 million